Full abbreviated new drug application approvals by the US Food and Drug Administration reached a new trough for fiscal year 2021 in June and now are on pace for the lowest annual total in four years.
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
